BioTuesdays

Category - Markets

DURECT

HCW assumes coverage of DURECT at buy

H.C. Wainwright has assumed coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and $3 price target. The stock was quoted at $1.02 in afternoon trading on Feb. 28. “Our focus is on the novel epigenetic regulator...

Cempra

Roth upgrades Cempra to buy

Roth Capital Partners upgraded Cempra (NASDAQ:CEMP) to “buy” and maintained its $8 price target after the company announced positive Phase 3 results in the first of two skin infection (ABSSSI) studies with Taksta. The...

Zynerba Pharmaceuticals Logo

Maxim starts Zynerba Pharma at buy

Maxim Group initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and 12-month price target of $32. The stock closed at $22.10 on Feb. 23. Analyst Lauren Chung writes that 2017 could be a...

Reata Pharma

Stifel starts Reata Pharma at buy

Stifel launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and $38 price target. The stock closed at $23.05 on Feb. 22. “Our positive thesis centers on what we see as blockbuster potential for...

ANI Pharmaceuticals

Roth downgrades ANI Pharma to neutral

Roth Capital Partners downgraded ANI Pharmaceuticals (NASDAQ:ANIP) to “neutral” from “buy,” pending the company’s 2017 financial guidance. Roth maintained its $69 price target for the stock, which was quoted at $59.53...

Argos Therapeutics

Stifel downgrades Argos to hold

Stifel downgraded Argos Therapeutics (NASDAQ:ARGS) to “hold” from “buy” and slashed its price target to $1.40 from $10 after an independent data monitoring committee (IDMC) recommended discontinuation of the ADAPT Phase...

Entellus Medical

BTIG downgrades Entellus Medical to neutral

BTIG downgraded Entellus Medical (NASDAQ:ENTL) to “neutral” from “buy,” saying that “something has gone off course” after the company reported Q4 results on Feb. 21. The stock closed at $17.08 yesterday. “For some time...

AnaptysBio

Stifel starts AnaptysBio at buy

Stifel launched coverage of AnaptysBio (NASDAQ:ANAB) with a “buy” rating and $30 price target. The stock closed at $23.89 on Feb. 17. “AnaptysBio, at its core, is a unique antibody generation company capable of directed...

ObsEva Logo

Leerink starts ObsEva at OP

Leerink initiated coverage of ObsEva SA (NASDAQ:OBSV) with an “outperform” rating and a 12-month price target of $21. The stock closed at $13.21 on Feb. 17. ObsEva is a clinical-stage biopharmaceutical company focused...

Medicure

Mackie ups Medicure price target to $14.70

Mackie Research Capital raised its price target for Medicure (TSX-V:MPH) to $14.70 from $6.90, reflecting the recent acquisition of a majority interest in Apicore as well as a change in the trend of Aggrastat...